Oruka Therapeutics, Inc. Proceeds from Sale and Maturity of Marketable Securities
Oruka Therapeutics, Inc. (ORKA) reported Proceeds from Sale and Maturity of Marketable Securities of $156.07 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-08-10
- Oruka Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2026-06-30 was $79.60M, a 29.49% decline year-over-year.
- Oruka Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2026-03-31 was $76.47M, a 12.27% decline year-over-year.
- Oruka Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-12-31 was $79.03M.
- Oruka Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $145.33M.
- Oruka Therapeutics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2025 was $424.42M.
- Oruka Therapeutics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2010 was $263.00K.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month | Proceeds from Sale and Maturity of Marketable Securities 114 month | Proceeds from Sale and Maturity of Marketable Securities 117 month | Proceeds from Sale and Maturity of Marketable Securities 120 month | Proceeds from Sale and Maturity of Marketable Securities 123 month | Proceeds from Sale and Maturity of Marketable Securities 126 month | Proceeds from Sale and Maturity of Marketable Securities 129 month | Proceeds from Sale and Maturity of Marketable Securities 132 month | Proceeds from Sale and Maturity of Marketable Securities 135 month | Proceeds from Sale and Maturity of Marketable Securities 138 month | Proceeds from Sale and Maturity of Marketable Securities 141 month | Proceeds from Sale and Maturity of Marketable Securities 144 month | Proceeds from Sale and Maturity of Marketable Securities 147 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $79.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $156.07M 10-Q · filed 2026-08-10 | $235.10M derived: sum of 3 quarters · filed 2026-08-10 | $380.43M derived: sum of 4 quarters · filed 2026-08-10 | ||||||||||||
| 2026-03-31 | $76.47M 10-Q · filed 2026-05-13 | $155.50M derived: sum of 2 quarters · filed 2026-05-13 | $300.83M derived: sum of 3 quarters · filed 2026-05-13 | $413.72M derived: sum of 4 quarters · filed 2026-08-10 | ||||||||||||
| 2025-12-31 | $79.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $224.36M derived: sum of 2 quarters · filed 2026-03-12 | $337.25M derived: sum of 3 quarters · filed 2026-08-10 | $424.42M 10-K · filed 2026-03-12 | ||||||||||||
| 2025-09-30 | $145.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $258.23M derived: sum of 2 quarters · filed 2026-08-10 | $345.39M 10-Q · filed 2025-11-12 | |||||||||||||
| 2025-06-30 | $112.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $200.06M 10-Q · filed 2026-08-10 | ||||||||||||||
| 2025-03-31 | $87.17M 10-Q · filed 2026-05-13 | |||||||||||||||
| 2014-03-31 | $15.37M 10-Q · filed 2014-05-13 | |||||||||||||||
| 2013-12-31 | $0.00 derived: 10-K 144 month − 10-Q 141 month · filed 2014-03-20 | $15.37M 10-K · filed 2014-03-20 | ||||||||||||||
| 2013-09-30 | $15.37M 10-Q · filed 2013-11-13 | |||||||||||||||
| 2013-06-30 | $15.37M 10-Q · filed 2013-08-13 | |||||||||||||||
| 2013-03-31 | $0.00 derived: 10-Q 135 month − 10-K 132 month · filed 2013-05-13 | $0.00 derived: sum of 2 quarters · filed 2013-05-13 | $0.00 derived: sum of 3 quarters · filed 2013-05-13 | $0.00 derived: sum of 4 quarters · filed 2013-05-13 | $15.37M 10-Q · filed 2013-05-13 | |||||||||||
| 2012-12-31 | $0.00 derived: 10-K 132 month − 10-Q 129 month · filed 2013-03-21 | $0.00 derived: sum of 2 quarters · filed 2013-03-21 | $0.00 derived: sum of 3 quarters · filed 2013-03-21 | $0.00 derived: sum of 4 quarters · filed 2013-03-21 | $15.37M 10-K · filed 2013-03-21 | |||||||||||
| 2012-09-30 | $0.00 derived: 10-Q 129 month − 10-Q 126 month · filed 2012-11-13 | $0.00 derived: sum of 2 quarters · filed 2012-11-13 | $0.00 derived: sum of 3 quarters · filed 2012-11-13 | $0.00 derived: sum of 4 quarters · filed 2012-11-13 | $15.37M 10-Q · filed 2012-11-13 | |||||||||||
| 2012-06-30 | $0.00 derived: 10-Q 126 month − 10-Q 123 month · filed 2012-08-13 | $0.00 derived: sum of 2 quarters · filed 2012-08-13 | $0.00 derived: sum of 3 quarters · filed 2012-08-13 | $0.00 derived: sum of 4 quarters · filed 2012-08-13 | $15.37M 10-Q · filed 2012-08-13 | |||||||||||
| 2012-03-31 | $0.00 derived: 10-Q 123 month − 10-K 120 month · filed 2012-05-14 | $0.00 derived: sum of 2 quarters · filed 2012-05-14 | $0.00 derived: sum of 3 quarters · filed 2012-05-14 | $15.37M 10-Q · filed 2012-05-14 | ||||||||||||
| 2011-12-31 | $0.00 derived: 10-K 120 month − 10-Q 117 month · filed 2012-03-27 | $0.00 derived: sum of 2 quarters · filed 2012-03-27 | $15.37M 10-K · filed 2012-03-27 | |||||||||||||
| 2011-09-30 | $0.00 derived: 10-Q 117 month − 10-Q 114 month · filed 2011-11-14 | $15.37M 10-Q · filed 2011-11-14 | ||||||||||||||
| 2011-06-30 | $15.37M 10-Q · filed 2011-08-15 | |||||||||||||||
| 2010-12-31 | $263.00K 10-K · filed 2012-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |